flucytosine has been researched along with HIV Infections in 66 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amphotericin B deoxycholate (AmBd) is the recommended induction treatment for HIV-associated cryptococcal meningitis (CM)." | 9.20 | Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. ( Bicanic, T; Bottomley, C; Brouwer, AE; Harrison, TS; Hosseinipour, MC; Jackson, A; Jarvis, JN; Limmathurotsakul, D; Loyse, A; Meintjes, G; Muzoora, C; Phulusa, J; Taseera, K; van der Horst, C; White, NJ; Wilson, D; Wood, R, 2015) |
| "The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)-recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)-associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines." | 5.69 | How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings? ( Boulware, DR; Harrison, TS; Hosseinipour, MC; Jarvis, JN; Lawrence, DS; Lortholary, O; Meintjes, G; Mosepele, M; Mwandumba, HC, 2023) |
| "Amphotericin B deoxycholate (AmBd) is the recommended induction treatment for HIV-associated cryptococcal meningitis (CM)." | 5.20 | Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. ( Bicanic, T; Bottomley, C; Brouwer, AE; Harrison, TS; Hosseinipour, MC; Jackson, A; Jarvis, JN; Limmathurotsakul, D; Loyse, A; Meintjes, G; Muzoora, C; Phulusa, J; Taseera, K; van der Horst, C; White, NJ; Wilson, D; Wood, R, 2015) |
| "HIV-uninfected CM patients who received high-dose fluconazole (800 mg/d) for initial therapy in Huashan Hospital were included in this retrospective study from January 2013 to December 2018." | 4.31 | Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not? ( Cheng, JH; Jiang, YK; Luo, Y; Wang, X; Zhao, HZ; Zhou, LH; Zhu, LP; Zhu, RS, 2023) |
| " We herein report an HIV-infected patient with disseminated cryptococcosis involving multiple organs including the blood, brain, lungs, and bone marrow, who developed progressive pancytopenia after initiation of anti-fungal treatment with liposomal amphotericin-B (L-AMB) and flucytosine (5FC)." | 4.12 | Progressive Cytopenia Developing during Treatment of Cryptococcosis in a Patient with HIV Infection and Bone Marrow Cryptococcal Infection. ( Ando, N; Aoki, T; Katsura, M; Kikuchi, Y; Koizumi, Y; Mizushima, D; Oka, S; Okuhama, A; Teruya, K; Tsukada, K; Watanabe, K; Yanagawa, Y, 2022) |
| "Induction phase weight and renal-adjusted doses of 1600mg and 2000mg/day FCZ for CM were safe and well tolerated except for increased GI side effects in the 2000mg/day dose, and had similar times to achieve CSF sterilization, but took significantly longer than AMB." | 3.30 | Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS ( Aberg, JA; Badal-Faesen, S; Bukuru, A; Clifford, DB; Hogg, E; Komarow, L; Lagat, D; Lalloo, UG; Langat, D; Larsen, RA; Mave, V; McKhann, A; Pillay, S; Samaneka, W; Supparatpinyo, K; Ticona, E, 2023) |
| "Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa." | 3.11 | Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. ( Boulware, DR; Boyer-Chammard, T; Chawinga, C; Chen, T; Comins, K; Harrison, TS; Hlupeni, A; Hope, W; Hosseinipour, MC; Jaffar, S; Jarvis, JN; Jjunju, S; Kagimu, E; Kanyama, C; Kasibante, J; Lalloo, DG; Lawrence, DS; Leeme, T; Lortholary, O; Loyse, A; Meintjes, G; Meya, DB; Molloy, SF; Mosepele, M; Moyo, M; Mpoza, E; Mutata, C; Muzoora, C; Mwandumba, HC; Mzinganjira, H; Ndhlovu, CE; Nuwagira, E; Rhein, J; Rutakingirwa, MK; Schutz, C; Siamisang, K; Singh, A; Ssebambulidde, K; Tugume, L; van Widenfelt, E; Wang, D; Youssouf, N, 2022) |
| "Cryptococcal meningitis is a devastating brain infection cause by encapsulated yeasts of the Cryptococcus genus." | 2.82 | Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going? ( Day, JN; Flower, B; Ngan, NTT, 2022) |
| "Mortality related to cryptococcal meningitis remains high, and novel treatment strategies are needed." | 2.77 | Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. ( Bekker, LG; Bicanic, T; Harrison, TS; Jarvis, JN; Meintjes, G; Rebe, K; Schutz, C; Williams, A; Williams, GN; Wood, R, 2012) |
| " Fluconazole at a dosage of 1200 mg per day is more fungicidal than at a dosage of 800 mg per day, but mortality rates remain unacceptably high." | 2.75 | Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. ( Harrison, TS; Hosseinipour, MC; Jackson, A; Jaffar, S; Jarvis, JN; Kamwendo, D; Kanyemba, C; Kenala, J; Namarika, D; Nussbaum, JC; Phulusa, J; van der Horst, CM, 2010) |
| " The bioavailability of the oral formulation may be reduced in late-stage HIV-infected patients in Thailand." | 2.73 | Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. ( Brouwer, AE; Chierakul, W; Day, N; Harrison, TS; Johnson, E; Rajanuwong, A; Teparrukkul, P; van Kan, HJ; Wuthiekanun, V, 2007) |
| "The major challenge in cryptococcal meningitis management has been the optimisation of induction phase treatment using the limited number of available medications, and major progress has recently been made." | 2.61 | Recent advances in managing HIV-associated cryptococcal meningitis. ( Alanio, A; Boyer-Chammard, T; Harrison, TS; Jarvis, JN; Lortholary, O; Temfack, E, 2019) |
| "Cryptococcal meningitis is a severe fungal infection that occurs primarily in the setting of advanced immunodeficiency and remains a major cause of HIV-related deaths worldwide." | 2.58 | Treatment for HIV-associated cryptococcal meningitis. ( Eshun-Wilson, I; Ford, N; Jarvis, JN; Li, T; Rouse, B; Shapiro, AE; Tenforde, MW, 2018) |
| "Symptoms of cryptococcal meningitis are non-specific: headache, fever, nausea, or altered mental state and behaviour." | 2.52 | [Cryptococcal meningitis]. ( Aliredjo, RP; de Jong, PY; de Sévaux, RG; Nooijen, S; van Spil, WE; Verhave, JC, 2015) |
| " The objective of this study was to compare the survival benefit between 5-FC (flucytosine) and fluconazole as second-line drugs given in combination with AmB." | 2.50 | Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis. ( Lin, DF; Lu, X; Shen, C; Yao, ZW, 2014) |
| " The optimal dosing of AmB remains unclear." | 2.44 | Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. ( Dedicoat, M; Dlamini, S; Paul, N; Sloan, D, 2008) |
| "Flucytosine-based treatment can be delivered in routine care in a middle-income country with a substantial survival benefit." | 1.72 | Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study. ( Black, J; Boretti, L; Garcia, A; Govender, NP; Greene, GS; Harrison, TS; Madua, M; Mashau, RC; Meintjes, G; Meiring, ST; Menezes, C; Nel, J; Quan, VC; Reddy, DL; Shroufi, A; Stacey, S; Trivino-Duran, L; Venter, M, 2022) |
| " Laboratory adverse events (grade 3 or 4), such as severe anemia, were less frequent with VCZ + 5FC use than with AmB-D combined with 5FC or Flu use." | 1.72 | Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China. ( Chen, Y; Harypursat, V; Lan, K; Lu, Y; Wu, Y; Xu, X; Yang, T; Yu, J; Zeng, Q; Zhang, W; Zhao, T; Zhou, G, 2022) |
| "He had multiple prior episodes of cryptococcal meningitis with complications necessitating ventriculoperitoneal shunt placement and was on suppressive fluconazole when he developed worsening brain manifestations." | 1.56 | Case Report: A Case of Severe Cryptococcal Immune Reconstitution Inflammatory Syndrome Presenting with Brain and Intradural Abscesses in an HIV Patient. ( Jeng, A; Kalinoski, T; Malenfant, J; Yim, C, 2020) |
| "The present study showed that mixed infections exist and could be of particular importance for care outcomes." | 1.51 | Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study. ( Bellet, V; Bertout, S; Chabrol, A; Delaporte, E; Doumbia, A; Drakulovski, P; Kakou, A; Kassi, FK; Krasteva, D; Landman, R; Menan, HEI; Reynes, J; Roger, F, 2019) |
| "Stroke is an increasing cause of morbidity and mortality amongst HIV infected persons." | 1.48 | Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report. ( Benjamin, LA; Ellis, JP; Harrison, TS; Heyderman, RS; Joekes, EC; Kalata, N; Kampondeni, S; Lalloo, DG, 2018) |
| "Flucytosine exposure was associated with a lower overall mortality rate (HR, 0." | 1.39 | Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. ( Bratton, EW; Chastain, CA; El Husseini, N; Juliano, JJ; Lee, MS; Perfect, JR; Poole, C; Stürmer, T; Weber, DJ, 2013) |
| "Most cases of cryptococcal meningitis occur in patients with HIV infection: the course and outcome of disease in the apparently immunocompetent is much more poorly understood." | 1.36 | A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. ( Baker, S; Campbell, JI; Chau, TT; Chuong, LV; Day, JN; Diep, PT; Duong, VA; Farrar, JJ; Hien, TT; Lalloo, DG; Mai, NH; Nghia, HD; Phu, NH; Sinh, DX, 2010) |
| "Acanthamoeba infection is a rare, difficult-to-treat, and often fatal, opportunistic parasitic infection in immunocompromised hosts, such as patients infected with HIV." | 1.33 | Successful treatment of Acanthamoeba rhinosinusitis in a patient with AIDS. ( Nachega, JB; Rombaux, P; Thomas, G; Weynand, B; Zech, F, 2005) |
| "Treatment with fluconazole seems to be an effective alternative in treatment of CNM." | 1.28 | [Fluconazole treatment of cryptococcal meningitis associated with HIV infection. Presentation of 4 cases]. ( Bernacer, B; Carrasco, R; Navarro, V; Nieto, A; Rodríguez, M; Roig, P; Salavert, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (7.58) | 18.2507 |
| 2000's | 13 (19.70) | 29.6817 |
| 2010's | 31 (46.97) | 24.3611 |
| 2020's | 17 (25.76) | 2.80 |
| Authors | Studies |
|---|---|
| Brouwer, AE | 2 |
| van Kan, HJ | 1 |
| Johnson, E | 1 |
| Rajanuwong, A | 1 |
| Teparrukkul, P | 1 |
| Wuthiekanun, V | 1 |
| Chierakul, W | 1 |
| Day, N | 1 |
| Harrison, TS | 14 |
| Barrett, K | 1 |
| Tavakoli, S | 1 |
| McGinity, M | 1 |
| Gilbert, A | 1 |
| Jarvis, JN | 11 |
| Lawrence, DS | 4 |
| Meya, DB | 2 |
| Kagimu, E | 1 |
| Kasibante, J | 1 |
| Mpoza, E | 1 |
| Rutakingirwa, MK | 1 |
| Ssebambulidde, K | 1 |
| Tugume, L | 1 |
| Rhein, J | 1 |
| Boulware, DR | 5 |
| Mwandumba, HC | 3 |
| Moyo, M | 2 |
| Mzinganjira, H | 1 |
| Kanyama, C | 2 |
| Hosseinipour, MC | 4 |
| Chawinga, C | 1 |
| Meintjes, G | 7 |
| Schutz, C | 3 |
| Comins, K | 1 |
| Singh, A | 1 |
| Muzoora, C | 3 |
| Jjunju, S | 1 |
| Nuwagira, E | 1 |
| Mosepele, M | 2 |
| Leeme, T | 1 |
| Siamisang, K | 1 |
| Ndhlovu, CE | 1 |
| Hlupeni, A | 1 |
| Mutata, C | 1 |
| van Widenfelt, E | 1 |
| Chen, T | 1 |
| Wang, D | 1 |
| Hope, W | 2 |
| Boyer-Chammard, T | 3 |
| Loyse, A | 6 |
| Molloy, SF | 2 |
| Youssouf, N | 1 |
| Lortholary, O | 7 |
| Lalloo, DG | 4 |
| Jaffar, S | 3 |
| Mashau, RC | 1 |
| Meiring, ST | 1 |
| Quan, VC | 1 |
| Nel, J | 1 |
| Greene, GS | 1 |
| Garcia, A | 1 |
| Menezes, C | 1 |
| Reddy, DL | 1 |
| Venter, M | 1 |
| Stacey, S | 1 |
| Madua, M | 1 |
| Boretti, L | 1 |
| Shroufi, A | 3 |
| Trivino-Duran, L | 1 |
| Black, J | 1 |
| Govender, NP | 3 |
| Zhao, T | 1 |
| Xu, X | 1 |
| Wu, Y | 1 |
| Zhang, W | 1 |
| Zeng, Q | 1 |
| Lu, Y | 1 |
| Yang, T | 1 |
| Zhou, G | 1 |
| Yu, J | 1 |
| Lan, K | 1 |
| Harypursat, V | 1 |
| Chen, Y | 1 |
| Zhao, HZ | 1 |
| Cheng, JH | 1 |
| Zhou, LH | 1 |
| Luo, Y | 1 |
| Zhu, RS | 1 |
| Jiang, YK | 1 |
| Wang, X | 1 |
| Zhu, LP | 1 |
| Ngan, NTT | 1 |
| Flower, B | 1 |
| Day, JN | 2 |
| Shapiro, AE | 2 |
| Tenforde, MW | 2 |
| Chiller, TM | 1 |
| Ford, N | 4 |
| Rajasingham, R | 2 |
| Ssali, A | 1 |
| Moshashane, N | 1 |
| Nabaggala, G | 1 |
| Maphane, L | 1 |
| Seeley, J | 1 |
| Lalloo, UG | 1 |
| Komarow, L | 1 |
| Aberg, JA | 1 |
| Clifford, DB | 1 |
| Hogg, E | 1 |
| McKhann, A | 1 |
| Bukuru, A | 1 |
| Lagat, D | 1 |
| Pillay, S | 1 |
| Mave, V | 1 |
| Supparatpinyo, K | 1 |
| Samaneka, W | 1 |
| Langat, D | 1 |
| Ticona, E | 1 |
| Badal-Faesen, S | 1 |
| Larsen, RA | 1 |
| Stott, KE | 1 |
| Ahmadu, A | 1 |
| Kajanga, C | 1 |
| Gondwe, E | 1 |
| Chimang'anga, W | 1 |
| Chasweka, M | 1 |
| Unsworth, J | 1 |
| Jimenez-Valverde, A | 1 |
| Jagota, B | 1 |
| Shah, RV | 1 |
| Harrison, T | 1 |
| Bive, BZ | 1 |
| Sacheli, R | 1 |
| Mudogo, CN | 1 |
| Zakayi, PK | 1 |
| Bontems, S | 1 |
| Lelo, GM | 1 |
| Hayette, MP | 1 |
| Temfack, E | 3 |
| Lawrence, D | 1 |
| Delliere, S | 1 |
| Lanternier, F | 1 |
| Alanio, A | 2 |
| Kassi, FK | 2 |
| Drakulovski, P | 2 |
| Bellet, V | 2 |
| Roger, F | 2 |
| Chabrol, A | 1 |
| Krasteva, D | 2 |
| Doumbia, A | 2 |
| Landman, R | 1 |
| Kakou, A | 1 |
| Reynes, J | 2 |
| Delaporte, E | 2 |
| Menan, HEI | 1 |
| Bertout, S | 2 |
| Kalinoski, T | 1 |
| Malenfant, J | 1 |
| Yim, C | 1 |
| Jeng, A | 1 |
| Vidal, JE | 1 |
| de Albuquerque Moraes, C | 1 |
| de Siqueira, REB | 1 |
| Miranda, NFB | 1 |
| Marcusso, R | 1 |
| de Oliveira, ACP | 1 |
| Chiller, T | 2 |
| Jordan, A | 1 |
| Denning, DW | 1 |
| Baptiste, S | 1 |
| Ribeiro, I | 2 |
| Van Cutsem, G | 1 |
| Miot, J | 1 |
| Leong, T | 1 |
| Takuva, S | 1 |
| Parrish, A | 1 |
| Dawood, H | 1 |
| Katsura, M | 1 |
| Okuhama, A | 1 |
| Koizumi, Y | 1 |
| Ando, N | 1 |
| Yanagawa, Y | 1 |
| Mizushima, D | 1 |
| Aoki, T | 1 |
| Tsukada, K | 1 |
| Teruya, K | 1 |
| Kikuchi, Y | 1 |
| Oka, S | 1 |
| Watanabe, K | 1 |
| Valérie, BA | 1 |
| Aboubakar, T | 1 |
| Kouakou, GA | 1 |
| Yavo, W | 1 |
| Menan, HIE | 1 |
| Johnson, WJ | 1 |
| Blice, JP | 1 |
| Lee, KK | 1 |
| Rouse, B | 1 |
| Li, T | 1 |
| Eshun-Wilson, I | 2 |
| Ellis, JP | 1 |
| Kalata, N | 2 |
| Joekes, EC | 1 |
| Kampondeni, S | 1 |
| Benjamin, LA | 1 |
| Heyderman, RS | 1 |
| Burry, J | 1 |
| Cohn, J | 1 |
| Koulla-Shiro, S | 1 |
| Mghamba, J | 1 |
| Ramadhani, A | 1 |
| Nyirenda, R | 1 |
| Aliyu, SH | 1 |
| Wilson, D | 2 |
| Le, T | 1 |
| Oladele, R | 1 |
| Lesikari, S | 1 |
| Mapoure, Y | 1 |
| Sini, V | 1 |
| Chanda, D | 1 |
| Shimwela, M | 1 |
| Lakhi, S | 1 |
| Ngoma, J | 1 |
| Gondwe-Chunda, L | 1 |
| Perfect, C | 1 |
| Andrieux-Meyer, I | 1 |
| Chan, A | 1 |
| Hosseinipour, M | 1 |
| Van der Horst, C | 2 |
| Klausner, JD | 1 |
| Heyderman, R | 1 |
| Lalloo, D | 1 |
| Day, J | 2 |
| Rodrigues, M | 1 |
| Denning, D | 1 |
| Migone, C | 2 |
| Doherty, M | 1 |
| Dromer, F | 3 |
| Stack, M | 1 |
| Bicanic, T | 4 |
| van Oosterhout, J | 1 |
| Mwaba, P | 1 |
| Kouanfack, C | 1 |
| Mfinanga, S | 1 |
| Govender, N | 1 |
| Garner, P | 1 |
| Li, Z | 1 |
| Liu, Y | 1 |
| Chong, Y | 1 |
| Li, X | 1 |
| Jie, Y | 1 |
| Zheng, X | 1 |
| Yan, Y | 1 |
| Bratton, EW | 1 |
| El Husseini, N | 1 |
| Chastain, CA | 1 |
| Lee, MS | 1 |
| Poole, C | 1 |
| Stürmer, T | 1 |
| Weber, DJ | 1 |
| Juliano, JJ | 1 |
| Perfect, JR | 1 |
| Banerjee, D | 1 |
| Burkard, L | 1 |
| Panepinto, JC | 1 |
| Yao, ZW | 1 |
| Lu, X | 1 |
| Shen, C | 1 |
| Lin, DF | 1 |
| Gariani, K | 1 |
| Rougemont, M | 1 |
| Renzi, G | 1 |
| Hibbs, J | 1 |
| Emonet, S | 1 |
| Schrenzel, J | 1 |
| Sohail, MA | 1 |
| Adnan Sohail, M | 1 |
| Ikram, U | 1 |
| van Spil, WE | 1 |
| Nooijen, S | 1 |
| de Jong, PY | 1 |
| Aliredjo, RP | 1 |
| de Sévaux, RG | 1 |
| Verhave, JC | 1 |
| Banoo, S | 1 |
| Bottomley, C | 1 |
| Taseera, K | 1 |
| Jackson, A | 2 |
| Phulusa, J | 2 |
| Limmathurotsakul, D | 1 |
| White, NJ | 1 |
| Wood, R | 3 |
| Córdoba, S | 1 |
| Isla, MG | 1 |
| Szusz, W | 1 |
| Vivot, W | 1 |
| Altamirano, R | 1 |
| Davel, G | 1 |
| Genebat, M | 1 |
| Mayorga-Buiza, MJ | 1 |
| Castillo-Ojeda, E | 1 |
| Rivero-Garvía, M | 1 |
| Márquez-Rivas, FJ | 1 |
| Jiménez-Mejías, ME | 1 |
| Pasqualotto, AC | 1 |
| Sloan, D | 1 |
| Dlamini, S | 1 |
| Paul, N | 1 |
| Dedicoat, M | 1 |
| Odds, FC | 1 |
| Nussbaum, JC | 1 |
| Namarika, D | 1 |
| Kenala, J | 1 |
| Kanyemba, C | 1 |
| Kamwendo, D | 1 |
| van der Horst, CM | 1 |
| Falci, DR | 1 |
| Lunardi, LW | 1 |
| Ramos, CG | 1 |
| Bay, MB | 1 |
| Aquino, VR | 1 |
| Goldani, LZ | 1 |
| Chau, TT | 1 |
| Mai, NH | 1 |
| Phu, NH | 1 |
| Nghia, HD | 1 |
| Chuong, LV | 1 |
| Sinh, DX | 1 |
| Duong, VA | 1 |
| Diep, PT | 1 |
| Campbell, JI | 1 |
| Baker, S | 1 |
| Hien, TT | 1 |
| Farrar, JJ | 1 |
| Nweze, EI | 1 |
| Ogbonnaya, UL | 1 |
| García-Lázaro, M | 1 |
| Salido, R | 1 |
| Arenas, C | 1 |
| Rivero, A | 1 |
| Khan, Z | 2 |
| Ahmad, S | 1 |
| Joseph, L | 1 |
| Chandy, R | 1 |
| Rebe, K | 1 |
| Williams, GN | 1 |
| Williams, A | 1 |
| Bekker, LG | 2 |
| Pan, W | 1 |
| Khayhan, K | 1 |
| Hagen, F | 1 |
| Wahyuningsih, R | 1 |
| Chakrabarti, A | 1 |
| Chowdhary, A | 1 |
| Ikeda, R | 1 |
| Taj-Aldeen, SJ | 1 |
| Imran, D | 1 |
| Sjam, R | 1 |
| Sriburee, P | 1 |
| Liao, W | 1 |
| Chaicumpar, K | 1 |
| Ingviya, N | 1 |
| Mouton, JW | 1 |
| Curfs-Breuker, I | 1 |
| Boekhout, T | 1 |
| Meis, JF | 1 |
| Klaassen, CH | 1 |
| Liao, CH | 1 |
| Chi, CY | 1 |
| Wang, YJ | 1 |
| Tseng, SW | 1 |
| Chou, CH | 1 |
| Ho, CM | 1 |
| Lin, PC | 1 |
| Ho, MW | 1 |
| Wang, JH | 1 |
| Martínez-Baltanás, A | 1 |
| Cuadrado, JM | 1 |
| Jover, F | 1 |
| Roig, P | 2 |
| Darder, M | 1 |
| Nachega, JB | 1 |
| Rombaux, P | 1 |
| Weynand, B | 1 |
| Thomas, G | 1 |
| Zech, F | 1 |
| Dannaoui, E | 1 |
| Abdul, M | 1 |
| Arpin, M | 1 |
| Michel-Nguyen, A | 1 |
| Piens, MA | 1 |
| Favel, A | 1 |
| Danko, JR | 1 |
| Roberts, A | 1 |
| Thakur, K | 1 |
| Singh, G | 1 |
| Agarwal, S | 1 |
| Rani, L | 1 |
| Barchiesi, F | 1 |
| Arzeni, D | 1 |
| Caselli, F | 1 |
| Scalise, G | 1 |
| Powderly, WG | 1 |
| Anil, S | 1 |
| Ellepola, AN | 1 |
| Samaranayake, LP | 1 |
| Carrasco, R | 1 |
| Salavert, M | 1 |
| Nieto, A | 1 |
| Bernacer, B | 1 |
| Rodríguez, M | 1 |
| Navarro, V | 1 |
| Weber, S | 1 |
| Polak-Wyss, A | 1 |
| Brockmeyer, NH | 1 |
| Hantschke, D | 1 |
| Olbricht, T | 1 |
| Hengge, UA | 1 |
| Goos, M | 1 |
| Nelson, MR | 1 |
| Bower, M | 1 |
| Smith, D | 1 |
| Reed, C | 1 |
| Shanson, D | 1 |
| Gazzard, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031] | Phase 2 | 50 participants (Actual) | Interventional | 2017-10-10 | Completed | ||
| A Multi-center, Prospective, Randomized Trial of Amphotericin B in the Initial Antifungal Therapy for Non-HIV Cryptococcal Meningitis Patients[NCT06178627] | Phase 4 | 250 participants (Anticipated) | Interventional | 2023-08-13 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for flucytosine and HIV Infections
| Article | Year |
|---|---|
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?
Topics: Adult; Amphotericin B; Antifungal Agents; Fluconazole; Flucytosine; Glucocorticoids; HIV Infections; | 2022 |
An updated systematic review of HIV-associated cryptococcal meningitis treatment strategies.
Topics: Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV Infectio | 2023 |
New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis.
Topics: Amphotericin B; Antifungal Agents; Antiretroviral Therapy, Highly Active; Cryptococcus; Drug Therapy | 2019 |
Treatment for HIV-associated cryptococcal meningitis.
Topics: Acetazolamide; Acute Disease; Adult; Amphotericin B; Antifungal Agents; Developing Countries; Drug A | 2018 |
Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.
Topics: Africa; Amphotericin B; Antifungal Agents; Coinfection; Cryptococcus neoformans; Developing Countrie | 2019 |
Recent advances in managing HIV-associated cryptococcal meningitis.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Flucytosine; HIV Infections; Humans; Meningitis, Cry | 2019 |
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.
Topics: Africa; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Asia; Fluconazole; | 2013 |
Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis.
Topics: Amphotericin B; Antifungal Agents; Coinfection; Drug Therapy, Combination; Fluconazole; Flucytosine; | 2014 |
[Cryptococcal meningitis].
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Female; Fluconazole; Flucyt | 2015 |
Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.
Topics: Acetazolamide; Acute Disease; Adult; Amphotericin B; Antifungal Agents; Antihypertensive Agents; Dev | 2008 |
Current approach to the acute management of cryptococcal infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; Cryp | 2000 |
8 trials available for flucytosine and HIV Infections
| Article | Year |
|---|---|
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
Topics: Administration, Oral; Adult; Antifungal Agents; Area Under Curve; Female; Flucytosine; Hemoglobins; | 2007 |
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
Topics: Administration, Oral; Africa South of the Sahara; AIDS-Related Opportunistic Infections; Amphoterici | 2022 |
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings?
Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans; | 2023 |
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antifungal Agents; Drug Therapy, Combinat | 2023 |
Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.
Topics: Adult; Amphotericin B; Anemia; Antifungal Agents; Blood Cell Count; Coinfection; Creatinine; Cryptoc | 2015 |
Amphotericin B: the higher the dose, the higher the toxicity.
Topics: Amphotericin B; Antifungal Agents; Dose-Response Relationship, Drug; Fluconazole; Flucytosine; HIV I | 2008 |
Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi.
Topics: Administration, Oral; Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Cerebro | 2010 |
Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiviral Agents; C | 2012 |
47 other studies available for flucytosine and HIV Infections
| Article | Year |
|---|---|
Intracranial Epstein-Barr virus-associated smooth muscle tumor with superimposed cryptococcal infection: A case report.
Topics: Adult; Amphotericin B; Antiretroviral Therapy, Highly Active; Cryptococcus neoformans; Epstein-Barr | 2022 |
Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study.
Topics: Adult; Antifungal Agents; Cross-Sectional Studies; Cryptococcosis; Female; Fluconazole; Flucytosine; | 2022 |
Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.
Topics: Amphotericin B; Antifungal Agents; Cohort Studies; Deoxycholic Acid; Drug Combinations; Drug Therapy | 2022 |
Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not?
Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans; | 2023 |
The acceptability of the AMBITION-cm treatment regimen for HIV-associated cryptococcal meningitis: Findings from a qualitative methods study of participants and researchers in Botswana and Uganda.
Topics: Antifungal Agents; Botswana; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV Infections; Hu | 2022 |
Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis.
Topics: Adult; Antifungal Agents; Bayes Theorem; Cryptococcus neoformans; Flucytosine; HIV Infections; Human | 2023 |
Correlation of antifungal susceptibility and sequence types within Cryptococcus neoformans VNI from HIV patients, and ERG11 gene polymorphism.
Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Democratic Republic of t | 2023 |
Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.
Topics: Adult; Amphotericin B; Antifungal Agents; Coinfection; Cryptococcosis; Cryptococcus; Cryptococcus ne | 2019 |
Case Report: A Case of Severe Cryptococcal Immune Reconstitution Inflammatory Syndrome Presenting with Brain and Intradural Abscesses in an HIV Patient.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Anti-Inflammatory Agents; Anti-Retroviral Agents | 2020 |
HIV-Associated Cryptococcal Meningitis Patients Treated with Amphotericin B Deoxycholate Plus Flucytosine under Routine Care Conditions in a Referral Center in São Paulo, Brazil.
Topics: Adult; Amphotericin B; Antifungal Agents; Brazil; Deoxycholic Acid; Drug Combinations; Drug Therapy, | 2021 |
Ending deaths from HIV-related cryptococcal meningitis by 2030.
Topics: Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Ag | 2021 |
Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa.
Topics: Adult; Antifungal Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Flucytosine; HIV Infecti | 2021 |
Progressive Cytopenia Developing during Treatment of Cryptococcosis in a Patient with HIV Infection and Bone Marrow Cryptococcal Infection.
Topics: Antifungal Agents; Bone Marrow; Cryptococcosis; Cryptococcus neoformans; Flucytosine; HIV Infections | 2022 |
Comparative typing analyses of clinical and environmental strains of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast.
Topics: Adult; Amphotericin B; Antifungal Agents; Chloramphenicol; Cote d'Ivoire; Cryptococcosis; Cryptococc | 2018 |
Bilateral Asymptomatic Cryptococcal Retinitis without Choroiditis or Vitritis.
Topics: Administration, Oral; Adult; Amphotericin B; Antifungal Agents; Choroiditis; Cryptococcosis; Cryptoc | 2018 |
Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Brain Ischemia; Cryptococcus neofor | 2018 |
Updating guidance for preventing and treating cryptococcal disease: how evidence and decisions interface.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Anti | 2018 |
Fluconazole plus flucytosine is a good alternative therapy for non-HIV and non-transplant-associated cryptococcal meningitis: A retrospective cohort study.
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcus; Deoxycholic Acid; Drug Combinations; Drug Th | 2019 |
Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Dru | 2013 |
Treating cryptococcal meningitis in people with HIV.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; | 2013 |
Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B.
Topics: Amphotericin B; Antifungal Agents; Aspergillus fumigatus; Candida albicans; Cryptococcosis; Cryptoco | 2014 |
Fulminant atypical Cryptococcus neoformans pneumonia confirmed by PLEX-ID.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Bronchoalveolar Lavage Fluid; Coinfection; | 2014 |
Flucytosine-induced colitis.
Topics: Antifungal Agents; Colitis; Diagnosis, Differential; Diarrhea; Flucytosine; HIV Infections; Humans; | 2014 |
Access to flucytosine for HIV-infected patients with cryptococcal meningitis – an urgent need.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Flucytosine; Health Services Accessibility | 2014 |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Argentina; Cryptococcosis; | 2016 |
Cryptococcal Infection of the Ventriculoperitoneal Shunt in an HIV-Infected Patient with an Excellent Immunovirologic Status.
Topics: Abdominal Abscess; Adult; Amphotericin B; Antifungal Agents; Antiretroviral Therapy, Highly Active; | 2017 |
In Candida albicans, resistance to flucytosine and terbinafine is linked to MAT locus homozygosity and multilocus sequence typing clade 1.
Topics: Antifungal Agents; Candida albicans; Candidiasis; DNA Fingerprinting; Drug Resistance, Fungal; Flucy | 2009 |
Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: analysis of safety and fungicidal activity.
Topics: Adult; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid; Colony Count, Microbial; Cryptococcus | 2010 |
A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Cryptococcus gattii; Cryptococcus neofor | 2010 |
A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Cryptococcus gattii; Cryptococcus neofor | 2010 |
A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Cryptococcus gattii; Cryptococcus neofor | 2010 |
A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Cryptococcus gattii; Cryptococcus neofor | 2010 |
Oral Candida isolates among HIV-infected subjects in Nigeria.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Cand | 2011 |
[Skin lesions and fever in an VIH-infected patient].
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Dermatomycoses; F | 2012 |
Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen.
Topics: Aged; Aged, 80 and over; Candida; Candidiasis; Child; DNA, Ribosomal; Drug Resistance, Fungal; Femal | 2012 |
Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes.
Topics: Asia; Cryptococcus neoformans; Drug Resistance, Fungal; Fluconazole; Flucytosine; Genetic Variation; | 2012 |
Different presentations and outcomes between HIV-infected and HIV-uninfected patients with Cryptococcal meningitis.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antigens, Fun | 2012 |
[Meningeal cryptococcosis as a sign of immune reconstitution syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; An | 2005 |
Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Disease Susceptibility; Fl | 2005 |
Successful treatment of Acanthamoeba rhinosinusitis in a patient with AIDS.
Topics: Acanthamoeba; Adult; AIDS-Related Opportunistic Infections; Amebiasis; Amebicides; Amphotericin B; A | 2005 |
Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococc | 2006 |
Images in HIV/AIDS. Pruritic cryptococcal skin lesions in an HIV-positive person.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Dia | 2006 |
Meningitis caused by Rhodotorula rubra in an human immunodeficiency virus infected patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid | 2007 |
[Focusing on therapy of systemic mycoses].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candidiasis; Dose-Response | 1995 |
Primary resistance to flucytosine among clinical isolates of Candida spp.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Microbial; Flucytosine; HIV Infections; Hu | 2000 |
Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candida albicans; | 2001 |
[Fluconazole treatment of cryptococcal meningitis associated with HIV infection. Presentation of 4 cases].
Topics: Administration, Oral; Adult; Amphotericin B; Drug Therapy, Combination; Female; Fluconazole; Flucyto | 1992 |
[The resistance behavior of yeast isolates from defined patient groups to 5-fluorocytosine].
Topics: Candida; Candidiasis; Candidiasis, Oral; Candidiasis, Vulvovaginal; Drug Resistance, Microbial; Fema | 1991 |
[Comparative study of the therapy of Candida esophagitis in HIV-1-infected patients with fluconazole or amphotericin B and flucytosine].
Topics: Amphotericin B; Candidiasis; Drug Therapy, Combination; Esophagitis; Female; Fluconazole; Flucytosin | 1991 |
The value of serum cryptococcal antigen in the diagnosis of cryptococcal infection in patients infected with the human immunodeficiency virus.
Topics: Amphotericin B; Antigens, Fungal; Cryptococcosis; Cryptococcus neoformans; Flucytosine; HIV Infectio | 1990 |